A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT ID: NCT06934226

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

752 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-15

Study Completion Date

2027-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: JNJ 77242113

Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.

Group Type EXPERIMENTAL

JNJ-77242113

Intervention Type DRUG

JNJ-77242113 will be administered orally.

Matching Placebo to Ustekinumab

Intervention Type DRUG

Matching placebo will be administered subcutaneously.

Arm 2: Placebo

Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.

Group Type PLACEBO_COMPARATOR

JNJ-77242113

Intervention Type DRUG

JNJ-77242113 will be administered orally.

Matching Placebo to JNJ-77242113

Intervention Type DRUG

Matching placebo will be administered orally.

Matching Placebo to Ustekinumab

Intervention Type DRUG

Matching placebo will be administered subcutaneously.

Arm 3: Ustekinumab

Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.

Group Type ACTIVE_COMPARATOR

JNJ-77242113

Intervention Type DRUG

JNJ-77242113 will be administered orally.

Matching Placebo to JNJ-77242113

Intervention Type DRUG

Matching placebo will be administered orally.

Ustekinumab

Intervention Type DRUG

Ustekinumab will be administered subcutaneously.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JNJ-77242113

JNJ-77242113 will be administered orally.

Intervention Type DRUG

Matching Placebo to JNJ-77242113

Matching placebo will be administered orally.

Intervention Type DRUG

Ustekinumab

Ustekinumab will be administered subcutaneously.

Intervention Type DRUG

Matching Placebo to Ustekinumab

Matching placebo will be administered subcutaneously.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

STELARA CNTO 1275

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
* Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
* Total investigator global assessment (IGA) \>=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria

* Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
* Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
* Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
* Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cahaba Research Inc

Birmingham, Alabama, United States

Site Status

California Dermatology & Clinical Research Institute

Encinitas, California, United States

Site Status

T Joseph Raoof Md Inc

Encino, California, United States

Site Status

First OC Dermatology

Fountain Valley, California, United States

Site Status

Dermatologist Medical Group of North County, Inc.

Oceanside, California, United States

Site Status

NorCal Clinical Research

Rocklin, California, United States

Site Status

Integrative Skin Science and Research

Sacramento, California, United States

Site Status

MedDerm Associates

San Diego, California, United States

Site Status

Southern California Dermatology

Santa Ana, California, United States

Site Status

Olive View-UCLA Education & Research Institute

Sylmar, California, United States

Site Status

University of Conn Health Center

Farmington, Connecticut, United States

Site Status

Driven Research LLC

Coral Gables, Florida, United States

Site Status

Bioclinical Research Alliance Inc.

Miami, Florida, United States

Site Status

Renstar Medical Research

Ocala, Florida, United States

Site Status

Forcare Clinical Research Inc

Tampa, Florida, United States

Site Status

Hamilton Research LLC

Alpharetta, Georgia, United States

Site Status

Northshore Medical Group

Skokie, Illinois, United States

Site Status

Indiana Clinical Trial Center

Plainfield, Indiana, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

Equity Medical

Bowling Green, Kentucky, United States

Site Status

Tufts Medical Center

Boston, Massachusetts, United States

Site Status

Metro Boston Clinical Partners

Brighton, Massachusetts, United States

Site Status

The Derm Institute of West Michigan

Caledonia, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Hamzavi Dermatology

Fort Gratiot, Michigan, United States

Site Status

Somerset Skin Centre

Troy, Michigan, United States

Site Status

Minnesota Clinical Study Center

New Brighton, Minnesota, United States

Site Status

Cleaver Dermatology

Kirksville, Missouri, United States

Site Status

MediSearch Clinical Trials

Saint Joseph, Missouri, United States

Site Status

Mount Sinai Doctors Dermatology

New York, New York, United States

Site Status

Sadick Research Group

New York, New York, United States

Site Status

Wilmington Dermatology Center

Wilmington, North Carolina, United States

Site Status

Optima Research

Boardman, Ohio, United States

Site Status

Apex Dermatology Mayfield Heights

Mayfield Heights, Ohio, United States

Site Status

Oregon Medical Research Center

Portland, Oregon, United States

Site Status

Oregon Dermatology and Research Center

Portland, Oregon, United States

Site Status

Clinical Research Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

UPMC Department of Dermatology

Pittsburgh, Pennsylvania, United States

Site Status

Health Concepts

Rapid City, South Dakota, United States

Site Status

Advanced Research Experts PLLC

Nashville, Tennessee, United States

Site Status

Arlington Research Center, Inc.

Arlington, Texas, United States

Site Status

Modern Research Associates PLLC

Dallas, Texas, United States

Site Status

Center for Clinical Studies

Houston, Texas, United States

Site Status

Progressive Clinical Research

San Antonio, Texas, United States

Site Status

Texas Dermatology and Laser Specialists

San Antonio, Texas, United States

Site Status

Center for Clinical Studies

Webster, Texas, United States

Site Status

Kalo Clinical Research

West Valley City, Utah, United States

Site Status

Frontier Derm Partners CRO, LLC

Mill Creek, Washington, United States

Site Status

Consultora Integral de Salud SRL

Barrio Gral Paz Cba Capital, , Argentina

Site Status

Instituto Medico De Alta Complejidad (IMAC)

Buenos Aires, , Argentina

Site Status

Mindout Research

Buenos Aires, , Argentina

Site Status

Instituto de Neumonologia y Dermatologia

Buenos Aires, , Argentina

Site Status

Buenos Aires Skin

CABA, , Argentina

Site Status

Investigaciones Medicas IMOBA SRL

CABA, , Argentina

Site Status

CIPREC

CABA, , Argentina

Site Status

Halitus Instituto Medico S.A. - Dermatologia y Estetica

Caba, , Argentina

Site Status

Mautalen Salud e Investigacion

CABA, , Argentina

Site Status

Hospital Italiano de Buenos Aires

CABA, , Argentina

Site Status

Instituto De Especialidades De La Salud SRL

Rosario, , Argentina

Site Status

MR Medicina Reumatologica

San Fernando, , Argentina

Site Status

Instituto de Investigaciones Medicas Tucuman

San Miguel de Tucumán, , Argentina

Site Status

Monash Medical Centre

Clayton, , Australia

Site Status

Cornerstone Dermatology

Coorparoo, , Australia

Site Status

Premier Specialists

Kogarah, , Australia

Site Status

The Alfred Hospital

Melbourne, , Australia

Site Status

Royal Melbourne Hospital

Melbourne, , Australia

Site Status

ISHI dermatology

Mitcham, , Australia

Site Status

Westmead Hospital

Westmead, , Australia

Site Status

Veracity Clinical Research

Woolloongabba, , Australia

Site Status

LKH Feldkirch

Feldkirch, , Austria

Site Status

Kepler Universitatsklinikum GmbH

Linz, , Austria

Site Status

Universtitatsklinikum St Polten

Sankt Pölten, , Austria

Site Status

Allgemeines Krankenhaus der Stadt Wien

Vienna, , Austria

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

AZ St. Lucas

Ghent, , Belgium

Site Status

Ghent University Hospital

Ghent, , Belgium

Site Status

Universitair Ziekenhuis Leuven

Leuven, , Belgium

Site Status

Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

Liège, , Belgium

Site Status

Dermatologie Maldegem

Maldegem, , Belgium

Site Status

Skincare Studio Inc Dermatology Clinical Trials

St. John's, Newfoundland and Labrador, Canada

Site Status

CCA Medical Research Corporation

Ajax, Ontario, Canada

Site Status

SimcoDerm Medical and Surgical Dermatology Centre

Barrie, Ontario, Canada

Site Status

Dermatrials Research

Hamilton, Ontario, Canada

Site Status

Lovegrove Dermatology

London, Ontario, Canada

Site Status

Lynderm Research Inc.

Markham, Ontario, Canada

Site Status

Alliance Clinical Trials

Waterloo, Ontario, Canada

Site Status

Innovaderm Research Inc.

Montreal, Quebec, Canada

Site Status

The Centre de recherche Saint-Louis

Québec, Quebec, Canada

Site Status

Aalborg Sygehus Syd

Aalborg, , Denmark

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

Gentofte Hospital

Hellerup, , Denmark

Site Status

Bispebjerg Hospital

København NV, , Denmark

Site Status

Odense University Hospital

Odense, , Denmark

Site Status

Sjællands University hospital

Roskilde, , Denmark

Site Status

Klinikum Augsburg

Augsburg, , Germany

Site Status

Fachklinik Bad Bentheim

Bad Bentheim, , Germany

Site Status

ISA - Interdisciplinary Study Association GmbH

Berlin, , Germany

Site Status

Universitatsklinikum Bonn

Bonn, , Germany

Site Status

Studienzentrum an der Hase GbR

Bramsche, , Germany

Site Status

Rosenpark Research GmbH

Darmstadt, , Germany

Site Status

Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden

Dresden, , Germany

Site Status

Derma-Study-Center Friedrichshafen GmbH

Friedrichshafen, , Germany

Site Status

Universitaetsklinikum Schleswig Holstein Campus Kiel

Kiel, , Germany

Site Status

Studienzentrum Dr Schwarz Germany

Langenau, , Germany

Site Status

Dermatologie Mahlow

Mahlow, , Germany

Site Status

Gemeinschaftspraxis Dres. Quist

Mainz, , Germany

Site Status

Universitaetsklinikum Muenster

Münster, , Germany

Site Status

Hautarztpraxis

Witten, , Germany

Site Status

Obudai Egeszsegugyi Centrum Kft

Budapest, , Hungary

Site Status

Uno Medical Trials Ltd.

Budapest, , Hungary

Site Status

Derma-B Kft

Debrecen, , Hungary

Site Status

Debreceni Egyetem Klinikai Kozpont

Debrecen, , Hungary

Site Status

Gyongyosi Bugat Pal Korhaz

Gyöngyös, , Hungary

Site Status

Synexus Magyarorszag Kft

Gyula, , Hungary

Site Status

Porcika Klinika - Vasarhelyi Sarkanyfu Kft.

Hódmezővásárhely, , Hungary

Site Status

Somogy Varmegyei Kaposi Mor Oktato Korhaz

Kaposvár, , Hungary

Site Status

Bacs-kiskun Megyei Korhaz

Kecskemét, , Hungary

Site Status

Allergo-Derm Bakos Kft.

Szolnok, , Hungary

Site Status

Medmare Egeszsegugyi Es Szolgaltato Bt.

Veszprém, , Hungary

Site Status

Specderm Poznanska sp j

Bialystok, , Poland

Site Status

Osteo-Medic s.c A. Racewicz, J Supronik

Bialystok, , Poland

Site Status

Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska

Elblag, , Poland

Site Status

Care Clinic Sp z o o

Katowice, , Poland

Site Status

Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna

Krakow, , Poland

Site Status

Dermed Centrum Medyczne Sp z o o

Lodz, , Poland

Site Status

Etyka Osrodek Badan Klinicznych

Olsztyn, , Poland

Site Status

SOLUMED Centrum Medyczne

Poznan, , Poland

Site Status

Velocity Skierniewice sp z o o

Skierniewice, , Poland

Site Status

Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej

Warsaw, , Poland

Site Status

Klinika Ambroziak Dermatologia

Warsaw, , Poland

Site Status

WroMedica

Wroclaw, , Poland

Site Status

Centrum Medyczne Oporow

Wroclaw, , Poland

Site Status

Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes

Braga, , Portugal

Site Status

Unidade Local De Saude Da Regiao De Leiria Epe

Leiria, , Portugal

Site Status

Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos

Lisbon, , Portugal

Site Status

Hosp. Cuf Descobertas

Lisbon, , Portugal

Site Status

Ulssa Hosp. Santo Antonio

Porto, , Portugal

Site Status

Hosp. Gral. Univ. Dr. Balmis

Alicante, , Spain

Site Status

Hosp. Univ. de Cruces

Barakaldo, , Spain

Site Status

Hosp. Clinic de Barcelona

Barcelona, , Spain

Site Status

Hosp. Univ. San Cecilio

Granada, , Spain

Site Status

Grupo Dermatologico Y Estetico Pedro Jaen

Madrid, , Spain

Site Status

Hosp. Univ. de La Princesa

Madrid, , Spain

Site Status

Hosp. Univ. 12 de Octubre

Madrid, , Spain

Site Status

Hosp. de Manises

Manises, , Spain

Site Status

Hosp. Clinico Univ. de Santiago

Santiago Compostela, , Spain

Site Status

Hosp. Virgen Macarena

Seville, , Spain

Site Status

Hosp. Ntra. Sra. de Valme

Seville, , Spain

Site Status

Hosp. Univ. I Politecni La Fe

Valencia, , Spain

Site Status

Hosp. de La Marina Baixa

Villajoyosa, , Spain

Site Status

Hosp. Clinico Univ. Lozano Blesa

Zaragoza, , Spain

Site Status

Hosp. Univ. Miguel Servet

Zaragoza, , Spain

Site Status

Dudley Group NHS Foundation Trust

Dudley, , United Kingdom

Site Status

London North West University Healthcare NHS Trust

Harrow, , United Kingdom

Site Status

The Queen Elizabeth Hospital NHS Foundation Trust

Kings Lynn, , United Kingdom

Site Status

Guys and St Thomas NHS Foundation Trust

London, , United Kingdom

Site Status

Royal Berkshire Hospital

Reading, , United Kingdom

Site Status

Salford Royal Hospital

Salford, , United Kingdom

Site Status

University Hospital Southampton

Southampton, , United Kingdom

Site Status

Mid Yorkshire NHS Trust

Wakefield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Canada Denmark Germany Hungary Poland Portugal Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

77242113PSO3006

Identifier Type: OTHER

Identifier Source: secondary_id

2024-515706-77-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

77242113PSO3006

Identifier Type: -

Identifier Source: org_study_id